نتائج البحث - "egfr inhibitors"

21

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

المؤلفون: Rama Suresh, Saiama N. Waqar, Haeseong Park, Benjamin R. Tan, Nikolaos A. Trikalinos, Sarah Larson, Kerry J. Williams, Daniel Morgensztern, A. Craig Lockhart, Andrea Wang-Gillam, Jingqin Luo, Ramaswamy Govindan, Brian A. Van Tine

المصدر: Cancer Chemother Pharmacol

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Toxicology, Article, Cohort Studies, Erlotinib Hydrochloride, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Mucositis, Humans, Pharmacology (medical), Epidermal growth factor receptor, Aged, EGFR inhibitors, Aged, 80 and over, Sirolimus, Pharmacology, Dose-Response Relationship, Drug, biology, business.industry, Middle Aged, medicine.disease, Rash, Temsirolimus, ErbB Receptors, Regimen, Treatment Outcome, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Mutation, Disease Progression, biology.protein, Female, Erlotinib, Phosphatidylinositol 3-Kinase, medicine.symptom, business, Progressive disease, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::883969f26c2a1384c7935fe7c7e39601Test
https://doi.org/10.1007/s00280-020-04183-0Test

22

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

المؤلفون: Yi-Long Wu, Ying Cheng, Jianying Zhou, Shun Lu, Yiping Zhang, Jun Zhao, Dong-Wan Kim, Ross Andrew Soo, Sang-We Kim, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Xiaoqing Liu, Daniel Shao Weng Tan, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, James Chih-Hsin Yang, Zhe Liu, Xi Chen, Mengzhao Wang, Shiying Yu, Helong Zhang, Jian Fang, Wei Li, Chih-Hsin Yang, Gee-Chen Chang, Te-Chun Hsia, Cheng-Ta Yang, Chin-Chou Wang, Byoung Chul Cho, Ki Hyeong Lee, Young-Chul Kim, Ho Jung An, In Sook Woo, Jae Yong Cho, Sang Won Shin, Jong-Seok Lee, Joo-Hang Kim, Seung Soo Yoo, Terufumi Kato, Naofumi Shinagawa, Shao Weng Daniel Tan, Lynette Si-Mien Ngo, Kananathan Ratnavelu, Azura Rozila Ahmad, Chong Kin Liam, Filippo de Marinis, Pierfrancesco Tassone, Amelia Insa Molla, Antonio Calles Blanco, Martin Emilio Lazaro Quintela, Enriqueta Felip Font, Anne-Marie Dingemans, Lynne Bui

المصدر: The Lancet Respiratory Medicine. 8:1132-1143

مصطلحات موضوعية: Male, Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Risk Assessment, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Gefitinib, Piperidines, Carcinoma, Non-Small-Cell Lung, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, media_common.cataloged_instance, 030212 general & internal medicine, European union, Lung cancer, Aged, Proportional Hazards Models, EGFR inhibitors, media_common, Chemotherapy, business.industry, Hazard ratio, Middle Aged, Proto-Oncogene Proteins c-met, Prognosis, medicine.disease, Survival Analysis, ErbB Receptors, Gene Expression Regulation, Neoplastic, Pyridazines, Pyrimidines, Treatment Outcome, 030228 respiratory system, Drug Resistance, Neoplasm, Mutation, Absolute neutrophil count, Female, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20318c347afef7410fb0f11cfa50f770Test
https://doi.org/10.1016/s2213-2600Test(20)30154-5

23

The next tier of EGFR resistance mutations in lung cancer

المؤلفون: Alena Heimsoeth, Hannah L. Tumbrink, Martin L. Sos

المصدر: Oncogene. 40:1-11

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::e82f29fa7de48a30a14bd4f49c232c71Test
https://doi.org/10.1038/s41388-020-01510-wTest

24

Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression

المؤلفون: Wei-Chung Cheng, Yuh Pyng Sher, Chia-Chien Lo, Guan-Chin Tseng, Yu-Kai Huang, Ching Chan Lin, Jin-Yuan Shih, Ting-Ting Kuo, K. S. Clifford Chao, Jennifer L. Hsu, Tzu-Hung Hsiao, Liang-Chuan Lai, Xian Sun, Mien Chie Hung, Chia-Fong Cho, Pei-Chih Lee, Yu-Huei Liu, Yu Sen Lin, Wei Chao Chang

المصدر: Theranostics

مصطلحات موضوعية: 0301 basic medicine, Lung Neoplasms, BASP1, Medicine (miscellaneous), Kaplan-Meier Estimate, combination therapy, Mice, 0302 clinical medicine, Arsenic Trioxide, Antineoplastic Combined Chemotherapy Protocols, Medicine, EGFR-TKI acquired resistance, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Lung, EGFR inhibitors, Feedback, Physiological, Brain Neoplasms, Brain, Prognosis, ErbB Receptors, 030220 oncology & carcinogenesis, Gene Knockdown Techniques, Adenocarcinoma, Tyrosine kinase, Research Paper, Signal Transduction, Brain Acid Soluble Protein 1, Adenocarcinoma of Lung, Nerve Tissue Proteins, 03 medical and health sciences, Cell Line, Tumor, Animals, Humans, Lung cancer, Protein Kinase Inhibitors, business.industry, Gene Expression Profiling, Cell Membrane, Membrane Proteins, medicine.disease, lung adenocarcinoma, Xenograft Model Antitumor Assays, Repressor Proteins, 030104 developmental biology, Membrane protein, Tumor progression, Drug Resistance, Neoplasm, Tissue Array Analysis, Mutation, Proteolysis, Cancer research, business, Brain metastasis

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2344f6f2a08d9c4a6bfcefe84f2dbda9Test
http://europepmc.org/articles/PMC7532684Test

25

Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review

المؤلفون: Ran Zuo, Yajie Wang, Peng Chen, Cuicui Zhang, Li Lin

المصدر: Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 9, Pp 2743-2748 (2020)

مصطلحات موضوعية: 0301 basic medicine, Pulmonary and Respiratory Medicine, Male, Lung Neoplasms, EGFR S768I, Afatinib, Case Report, Adenocarcinoma of Lung, Case Reports, lcsh:RC254-282, 03 medical and health sciences, 0302 clinical medicine, medicine, Humans, Osimertinib, Epidermal growth factor receptor, Lung cancer, Protein Kinase Inhibitors, EGFR inhibitors, Aged, rare mutation, biology, business.industry, EGFR G724S, General Medicine, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, epidermal growth factor receptor (EGFR), ErbB Receptors, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Icotinib, Mutation, Cancer research, biology.protein, Adenocarcinoma, Female, business, Tyrosine kinase, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99e4e5551796d49019216b64adb617baTest
http://europepmc.org/articles/PMC7471019Test

26

Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment

المؤلفون: Kulbhushan Tikoo, Sandeep Singh, Nisha Sharma, Sajal Biswas, Gaurav Joshi, Raj Kumar, Tashvinder Singh, Manvendra Kumar, Zahid Rafiq Bhat, Sahil Arora

المصدر: Molecules
Volume 26
Issue 5
Molecules, Vol 26, Iss 1490, p 1490 (2021)

مصطلحات موضوعية: Lung Neoplasms, Pharmaceutical Science, 01 natural sciences, Analytical Chemistry, chemistry.chemical_compound, T790M, Carcinoma, Non-Small-Cell Lung, Drug Discovery, Epidermal growth factor receptor, biology, Imidazoles, Gefitinib, ErbB Receptors, Molecular Docking Simulation, imidazo[1,2-a]quinoxaline, Chemistry (miscellaneous), Molecular Medicine, Erlotinib, medicine.drug, Antineoplastic Agents, mutant EGFR inhibitors, Article, lcsh:QD241-441, Erlotinib Hydrochloride, Inhibitory Concentration 50, Structure-Activity Relationship, anticancer agents, Quinoxaline, lcsh:Organic chemistry, Cell Line, Tumor, Quinoxalines, medicine, Humans, Physical and Theoretical Chemistry, Lung cancer, Protein Kinase Inhibitors, Cell Proliferation, 010405 organic chemistry, Organic Chemistry, non-covalent EGFR inhibitors, Wild type, Cancer, medicine.disease, 0104 chemical sciences, respiratory tract diseases, 010404 medicinal & biomolecular chemistry, chemistry, A549 Cells, Drug Resistance, Neoplasm, Mutation, Cancer research, biology.protein, Drug Screening Assays, Antitumor

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c3beb00e5f569c499c49be90ff8547Test
http://europepmc.org/articles/PMC7967119Test

27

LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

المؤلفون: Yingqiang Liu, Mengzhen Lai, Shan Li, Yanan Wang, Fang Feng, Tao Zhang, Linjiang Tong, Mengge Zhang, Hao Chen, Yi Chen, Peiran Song, Yan Li, Gang Bai, Yi Ning, Haotian Tang, Yan Fang, Xiaoyun Lu, Meiyu Geng, Ke Ding, Ker Yu, Hua Xie, Jian Ding

المصدر: Cancer science. 113(2)

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59b7db792eafed79fde7e0631854a57cTest
https://pubmed.ncbi.nlm.nih.gov/34855271Test

28

Development of triple mutant T790M/C797S allosteric EGFR inhibitors: a computational approach

المؤلفون: Prasad V.L.S. Burra, Deepak K. Lokwani, Kshipra S. Karnik, Ishudeep Singh Narula, Pravin S. Wakte, Aniket P. Sarkate

المصدر: Journal of Biomolecular Structure and Dynamics. 39:5376-5398

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7dca1262857426871d50050ba20e810dTest
https://doi.org/10.1080/07391102.2020.1786460Test

29

Feedback activation of EGFR is the main cause for STAT3 inhibition-irresponsiveness in pancreatic cancer cells

المؤلفون: Jiayuh Lin, Chenglong Li, Zhiguo Liu, Ri Cui, Liangxing Wang, Lehe Yang, Chengguang Zhao, Guang Liang, Youqun Xiang, Huang Xiaoying, Xiaojing Du, Congying Xie, Yun Yu, Feng Zhou

المصدر: Oncogene. 39:3997-4013

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::8b5bbf5117b09383646c8d43ff57a24aTest
https://doi.org/10.1038/s41388-020-1271-yTest

30

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

المؤلفون: Guoqing Qian, Jack L. Arbiser, Songqing Fan, Shi-Yong Sun, Hongjing Zang, Taofeek K. Owonikoko, Suresh S. Ramalingam

المصدر: Molecular Oncology, Vol 14, Iss 4, Pp 882-895 (2020)
Molecular Oncology

مصطلحات موضوعية: 0301 basic medicine, Honokiol, Cancer Research, Lung Neoplasms, Cell, honokiol, chemistry.chemical_compound, T790M, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Osimertinib, Epidermal growth factor receptor, Research Articles, EGFR inhibitors, Aniline Compounds, biology, Chemistry, apoptosis, Drug Synergism, General Medicine, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, ErbB Receptors, medicine.anatomical_structure, Oncology, osimertinib, 030220 oncology & carcinogenesis, Molecular Medicine, Research Article, EGFR, Mice, Nude, lcsh:RC254-282, Lignans, 03 medical and health sciences, Cell Line, Tumor, Genetics, medicine, Animals, Humans, Lung cancer, Protein Kinase Inhibitors, Acrylamides, Biphenyl Compounds, acquired resistance, medicine.disease, Antineoplastic Agents, Phytogenic, lung cancer, 030104 developmental biology, Drug Resistance, Neoplasm, Apoptosis, Mutation, Cancer research, biology.protein

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dd3809707c036d669b68eddbc568407Test
https://doi.org/10.1002/1878-0261.12645Test

تنقيح النتائج